Emerging therapies in rosacea.
Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients.
Department of Dermatology, Harrogate District Hospital, United Kingdom. Electronic address: Alison.layton@hhc-tr.northy.nhs.uk.
Alison
A
Layton
Diane
D
Thiboutot
D000900:Anti-Bacterial Agents; D000977:Antiparasitic Agents / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D004890:Erythema / Q000188:drug therapy; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use; D008924:Mite Infestations / Q000188:drug therapy; D026023:Permethrin / Q000627:therapeutic use; D012393:Rosacea / Q000188:drug therapy* / Q000469:parasitology / Q000503:physiopathology
D000900:Anti-Bacterial Agents; D000977:Antiparasitic Agents; D016207:Cytokines; D026023:Permethrin; D007559:Ivermectin; D004318:Doxycycline
SDD; carvedilol; ivermectin; medical therapy; permethrin; rosacea; subantimicrobial dose doxycycline; subantimicrobial-dose doxycycline